Unicycive Therapeutics (UNCY) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($253.5 million vs $112.6 million), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | UNCY | VCRE |
|---|---|---|
| Share price | $4.11 | $9.00 |
| Market cap | $112.59M | $253.48M |
| 1-day change | +0.98% | +2.04% |
| YTD return | -28.77% | — |
| 1-year return | -13.11% | — |
| 5-year return | -84.91% | — |
| Forward P/E | 2.44 | — |
| EPS (TTM) | $-1.72 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.74 | $17.80 |
| 52-week low | $3.93 | $7.88 |
| Distance from 52-week high | -52.97% | -49.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +591.00% | +268.44% |
| Average volume | 834.69K | 16.10K |
| Shares outstanding | 27.39M | 28.16M |
| Employees | 21 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vicore Pharma AB is about 2.3 times larger than Unicycive Therapeutics by market value ($253.48M vs $112.59M).
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
UNCY vs VCRE FAQ
Which is bigger, Unicycive Therapeutics or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $253.48M compared with $112.59M for Unicycive Therapeutics (UNCY).
Are Unicycive Therapeutics and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.